{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:41:45Z","timestamp":1792600905043,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.dld.2024.04.021","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T19:49:01Z","timestamp":1720295341000},"page":"1442-1451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?"],"prefix":"10.1016","volume":"56","author":[{"given":"Maria Letizia","family":"Petroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0554-7504","authenticated-orcid":false,"given":"Federica","family":"Perazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2407-9860","authenticated-orcid":false,"given":"Giulio","family":"Marchesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2024.04.021_bib0001","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experience with an hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.dld.2024.04.021_bib0002","unstructured":"Matsubayashi T. Drug development for nonalcoholic steatohepatitis (NASH) with fibrosis: a regulatory perspective. In: Available at: https:\/\/sbiaevents.com\/files2\/NASH-Webinar-January-2021.pdf.; 2021. p. Accessed March 28, 2024."},{"key":"10.1016\/j.dld.2024.04.021_bib0003","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0004","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.04.021_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0006","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.04.021_bib0007","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/liv.13743","article-title":"Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population","volume":"38","author":"Petta","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2024.04.021_bib0008","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cgh.2018.08.069","article-title":"Range of normal liver stiffness and factors associated with increased stiffness measurements in apparently healthy individuals","volume":"17","author":"Bazerbachi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0009","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis","volume":"8","author":"Mozes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.dld.2024.04.021_bib0010","first-page":"S61","article-title":"Therapy of NAFLD: insulin sensitizing agents","volume":"40","author":"Caldwell","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.dld.2024.04.021_bib0011","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0012","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0013","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0014","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.04.021_bib0015","unstructured":"GENFIT: GENFIT: Announces results from interim analysis of RESOLVE-IT phase 3 trial of elafibranor in adults with NASH and fibrosis. In: https:\/\/www.globenewswire.com\/news-release\/2020\/05\/11\/2031418\/0\/en\/GENFIT-Announces-Results-from-Interim-Analysis-of-RESOLVE-IT-Phase-3-Trial-of-Elafibranor-in-Adults-with-NASH-and-Fibrosis.html. GlobeNewswire, 2020."},{"key":"10.1016\/j.dld.2024.04.021_bib0016","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0017","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-alpha\/gamma agonist, for treatment of NAFLD: A randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.04.021_bib0018","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 tial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0019","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0020","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2024.04.021_bib0021","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.04.021_bib0022","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.cgh.2006.09.025","article-title":"Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis","volume":"4","author":"Dufour","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0023","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.23727","article-title":"High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Leuschner","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.04.021_bib0024","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2010.08.030","article-title":"A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis","volume":"54","author":"Ratziu","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0025","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0026","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.04.021_bib0027","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.04.021_bib0028","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.04.021_bib0029","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jhep.2020.03.024","article-title":"Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study","volume":"73","author":"Newsome","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0031","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.04.021_bib0032","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis","volume":"72","author":"Harrison","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0033","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab Is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.04.021_bib0034","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0035","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.04.021_bib0036","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.04.021_bib0037","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc teatment for adults with nonalcoholic steatohepatitis and fibrosis: Final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.04.021_bib0038","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to teat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0039","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.04.021_bib0040","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0041","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.609110","article-title":"Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: A meta-analysis","volume":"12","author":"Wong","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.dld.2024.04.021_bib0043","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0044","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-022-01140-3","article-title":"Effects of hepatic impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide","volume":"61","author":"Urva","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dld.2024.04.021_bib0045","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: A 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dld.2024.04.021_bib0046","first-page":"11","article-title":"Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials","author":"Mantovani","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.dld.2024.04.021_bib0047","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.04.021_bib0048","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0049","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0050","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0051","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.04.021_bib0052","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0053","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0054","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0055","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.04.021_bib0056","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/jgh.13856","article-title":"The Asia-Pacific Working Party on non-alcoholic fatty liver disease guidelines 2017-Part 2: Management and special groups","volume":"33","author":"Chitturi","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0057","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.dld.2021.04.029","article-title":"Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)","volume":"54","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2024.04.021_bib0058","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0059","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.04.021_bib0060","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.04.021_bib0061","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0062","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/hep.32315","article-title":"Placebo effect on progression and regression in NASH: Evidence from a meta-analysis","volume":"75","author":"Ng","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.04.021_bib0063","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/hep.28392","article-title":"Dalle Grave R. Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice","volume":"63","author":"Marchesini","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.04.021_bib0064","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2012.11.031","article-title":"Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease","volume":"58","author":"Centis","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12170-021-00680-w","article-title":"A review of telemedicine interventions for weight loss","volume":"15","author":"Ufholz","year":"2021","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"10.1016\/j.dld.2024.04.021_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.918982","article-title":"Editorial: mHealth for non-communicable diseases","volume":"10","author":"Hsu","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.dld.2024.04.021_bib0067","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/nu15030792","article-title":"Lifestyle intervention in NAFLD: Long-term diabetes incidence in subjects treated by web- and group-based programs","volume":"15","author":"Petroni","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.dld.2024.04.021_bib0068","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/apt.17768","article-title":"Long-term follow-up of web-based and group-based behavioural intervention in NAFLD in a real world clinical setting","volume":"59","author":"Petroni","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2024.04.021_bib0069","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: A systematic review and meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0070","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1007\/s11695-022-06011-1","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"32","author":"Zhou","year":"2022","journal-title":"Obes Surg"},{"key":"10.1016\/j.dld.2024.04.021_bib0071","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.soard.2017.09.511","article-title":"Impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004-2012","volume":"14","author":"McCarty","year":"2018","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.dld.2024.04.021_bib0072","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: A review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dld.2024.04.021_bib0073","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: A prespecified analysis of the STEP-HFpEF trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.dld.2024.04.021_bib0074","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.04.021_bib0075","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - A phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0076","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/14656566.2023.2208746","article-title":"Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes","volume":"24","author":"Brodosi","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.dld.2024.04.021_bib0077","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0078","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/2229-3485.106383","article-title":"Placebo in clinical trials","volume":"4","author":"Gupta","year":"2013","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.dld.2024.04.021_bib0079","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.04.021_bib0080","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jhep.2023.04.035","article-title":"A global research priority agenda to advance public health responses to fatty liver disease","volume":"79","author":"Lazarus","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.04.021_bib0081","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2024.04.021_bib0082","doi-asserted-by":"crossref","first-page":"e00082","DOI":"10.1002\/edm2.82","article-title":"Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study","volume":"2","author":"Petroni","year":"2019","journal-title":"Endocrinol Diab Metab"},{"key":"10.1016\/j.dld.2024.04.021_bib0083","article-title":"Emerging treatment options for sarcopenia in chronic liver disease","volume":"11","author":"Kim","year":"2021","journal-title":"Life (Basel)"},{"key":"10.1016\/j.dld.2024.04.021_bib0084","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/eurjpc\/zwad316","article-title":"Long-term lifestyle change and risk of mortality and Type 2 diabetes in patients with cardiovascular disease","volume":"31","author":"Bonekamp","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.dld.2024.04.021_bib0085","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2337\/dc22-1024","article-title":"Combination of multiple low-risk lifestyle behaviors and incident type 2 diabetes: A systematic review and dose-response meta-analysis of prospective cohort studies","volume":"46","author":"Khan","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dld.2024.04.021_bib0086","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2024.04.021_bib0087","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824007229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824007229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T15:34:53Z","timestamp":1732376093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865824007229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":87,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1590865824007229"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2024.04.021","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2024.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}